Clinical trials
Squamous Cell Lung Cancer clinical trials
Below are recruiting squamous cell lung cancer clinical trials, each written for real people, not researchers. We’re tracking 675 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06780111RecruitingPhase 1/Phase 2
Combination therapy study for advanced esophageal cancer
This trial tests new drug combinations for people with advanced squamous cell cancer of the esophagus that hasn't been treated yet. It aims to see if these combinations can shrink tumors and help patients live longer.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT05456256RecruitingPhase 2
LP-300 plus chemo for lung cancer in never-smokers
This Phase 2 trial tests LP-300 with carboplatin and pemetrexed to treat advanced lung adenocarcinoma in people who have never smoked. It may help shrink tumors and slow the disease in a specific genetic group of lung cancer.
Beverly Hills, CaliforniaAges 18 years+ - NCT06321484RecruitingPhase 1
NK cell therapy for recurrent platinum-resistant ovarian cancer
This trial tests a new type of immune cell therapy (CIML NK cells) given directly into the abdomen for women with ovarian cancer that has come back and is now resistant to standard platinum chemotherapy. The goal is to see if these specially trained cells can fight the cancer safely.
Boston, MassachusettsAges 18–85 - NCT05507411RecruitingPhase 2
Watch-and-wait after chemo-radiation plus immunotherapy for esophagus cancer
This Phase 2 study tests whether adding an immunotherapy drug (camrelizumab) to standard chemo-radiation can help some people with operable esophagus cancer avoid immediate surgery, using a “watch and wait” approach. If it works, it may reduce the need for early surgery for carefully selected patients.
Hanzhou, ZhejiangAges 18–75 - NCT06187597RecruitingPhase 2
Toripalimab after chemoradiation for older esophageal cancer
This study tests whether adding a drug called toripalimab after standard chemoradiation can help older adults with esophageal cancer. The goal is to see if this treatment can keep the cancer from coming back after initial therapy.
Guangzhou, GuangdongAges 70–85 - NCT07457528RecruitingPhase 2
Chemo, radiation, and immune therapy before surgery for esophageal cancer
This trial tests a combination of chemotherapy, radiation, and two targeted drugs (serplulimab and nimotuzumab) given before surgery for a certain type of esophageal cancer. It aims to see if this approach can safely improve outcomes.
Tianjin, Tianjin MunicipalityAges 18–75 - NCT04807673RecruitingPhase 3
Pembrolizumab before surgery versus chemoradiation for esophageal cancer
This Phase 3 study compares two treatment plans before surgery for locally advanced esophageal squamous cell carcinoma. It tests whether adding pembrolizumab (an immune therapy) to chemotherapy improves outcomes compared with standard chemoradiation.
Tianjin, Tianjin MunicipalityAges 18–75 - NCT06725368RecruitingPhase 2
Chemo plus cetuximab after pembrolizumab for head and neck cancer
This trial tests a combination of two chemotherapy drugs (carboplatin and paclitaxel) plus a targeted therapy (cetuximab) for people with advanced head and neck cancer that has gotten worse after treatment with pembrolizumab (with or without initial chemotherapy). The goal is to see if this new combination can shrink tumors or slow the cancer's growth.
Ars-LaquenexyAges 18 years+ - NCT07176000Recruiting
Helping tribal members get lung cancer screening
This study tests a program to help people in tribal communities get screened for lung cancer. It may help you get a low-dose CT scan to check for lung cancer early, when it’s easier to treat.
Auburn, WashingtonAges 18 years+ - NCT07501650RecruitingPhase 1
Pembrolizumab plus ultrasound bubbles for head and neck cancer
This trial combines the immunotherapy drug pembrolizumab (Keytruda) with a special ultrasound technique that uses tiny bubbles to make the treatment work better. It is for people with HPV-negative head and neck cancer that has come back or spread to other parts of the body.
Philadelphia, PennsylvaniaAges 18 years+ - NCT07314216RecruitingPhase 2
Firmonertinib plus radiation for stage III lung cancer with rare EGFR mutations
This trial tests whether combining the targeted pill firmonertinib with radiation therapy can help people with stage III non-small cell lung cancer that has certain rare EGFR mutations. It is for those whose cancer cannot be removed by surgery.
Changsha, HunanAges 18 years+ - NCT06810895Enrolling by invitation
Immunotherapy plus chemo for recurrent cervical cancer
This trial tests a new immunotherapy drug called cadonilimab (AK104) combined with standard chemotherapy for women whose small cell neuroendocrine cervical cancer has returned or spread. The goal is to see if this combination helps shrink tumors or slow the cancer better than chemotherapy alone.
WuhanAges 18–75 - NCT06272214RecruitingPhase 2
Adjuvant radiotherapy for esophageal cancer after immunotherapy
This trial tests if adding radiation therapy after surgery improves outcomes for people with esophageal squamous cell cancer who received immunotherapy and chemotherapy before surgery but did not achieve a complete response. It aims to see if this approach can lower the chance of the cancer coming back.
Hangzhou, ZhejiangAges 18–75 - NCT05392413Recruiting
Predicting who benefits from PD-1 antibody for esophageal cancer
This study uses an “immune indicator model” to help predict how well a PD-1 antibody (a cancer-fighting immune drug) works when combined with chemotherapy for stage IV esophageal squamous cell cancer. If you qualify, you receive the treatment and the researchers also look for immune-related signs that may explain who benefits most.
GuangzhouAges 18–75 - NCT04681469RecruitingPhase 2
Niraparib plus immunotherapy for HPV-negative head and neck cancer
This Phase 2 study tests a cancer “induction then maintenance” plan using a PARP inhibitor (niraparib) along with immunotherapy (TSR-042) in people with HPV-negative head and neck squamous cell cancer. If it works, it may improve control of the cancer after surgery by boosting the immune system and targeting cancer cells’ DNA repair.
BresciaAges 18 years+ - NCT05775419Recruiting
Chemo and radiation, with or without extra chemo after
This trial compares standard chemo plus radiation versus the same treatment plus extra “consolidation” chemo afterward. It’s for people with a type of esophageal cancer that can’t be removed with surgery, to see if the added treatment works better and is still safe.
Nanjing, JiangsuAges 18–70 - NCT06399926Recruiting
Pemetrexed via Ommaya for lung cancer in brain lining
This study tests whether a drug called pemetrexed, given directly into the fluid around your brain through a small implanted device, is safe and effective for treating lung cancer that has spread to the lining of the brain. It is for people whose cancer has a specific genetic change (EGFR, ALK, or ROS1) and who have already tried standard targeted pills that no longer control their disease.
Changsha, HunanAges 18 years+ - NCT06354140RecruitingPhase 2
Tislelizumab plus S-1 for esophageal cancer after surgery
This trial tests a combination of the immunotherapy drug tislelizumab and the chemotherapy drug S-1 for people with a specific type of esophageal cancer that still has some cancer cells in the main tumor but no cancer in lymph nodes after surgery. The goal is to see if this treatment can help prevent the cancer from coming back.
Chongqing, Chongqing MunicipalityAges 18–75 - NCT06510660RecruitingPhase 2
Immunotherapy and Chemoradiation for Advanced Esophageal Cancer
This trial tests a combination of immunotherapy (adebrelimab) plus standard chemotherapy and radiation for people with advanced esophageal cancer that cannot be removed by surgery. The goal is to see if adding the immunotherapy before and during chemoradiation helps control the cancer better.
Fuzhou, FujianAges 18–70 - NCT06646588RecruitingPhase 2
Study of fruquintinib, tislelizumab, and radiation for esophageal cancer
This trial tests a combination of two drugs (fruquintinib and tislelizumab) followed by radiation therapy for people with advanced esophageal squamous cell carcinoma. The goal is to see if this approach can help shrink tumors and improve outcomes.
Shijiazhuang, HebeiAges 18 years+ - NCT07624318Recruiting
TROP2 Lung Cancer Tissue Study
This research study analyzes lung cancer tissue samples to understand a protein called TROP2 and how it might help guide treatment decisions. You may qualify if you have non-squamous lung cancer and haven't received prior systemic chemotherapy or immunotherapy for advanced disease.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07627347Recruiting
Anlotinib and Bemocizumab for Early Esophageal Cancer
This study tests two drugs (anlotinib and bemocizumab) given before surgery to shrink esophageal squamous cell carcinoma (a type of throat cancer). The goal is to see if this combination helps patients have better outcomes and fewer side effects.
Guangzhou, GuangdongAges 18–70 - NCT07586202RecruitingPhase 2
Testing New Drug Combinations Before Lung Cancer Surgery
This trial tests whether giving new drugs (amivantamab plus either lazertinib or chemotherapy) before surgery helps people with a specific type of lung cancer that can be removed. The goal is to shrink tumors and improve surgery outcomes.
Duarte, CaliforniaAges 18 years+ - NCT07572864RecruitingPhase 2
Immunotherapy and vaccine before surgery for head and neck cancer
This trial tests a new combination of immunotherapy (a drug that helps your immune system fight cancer) and a mitochondrial vaccine given before surgery for head and neck squamous cell carcinoma. The goal is to help reduce cancer recurrence and improve survival after surgery.
Chengdu, SichuanAges 18 years+
Hear when a new Squamous Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for squamous cell lung cancer?
- Yes. Clin2 currently lists 675 recruiting squamous cell lung cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a squamous cell lung cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a squamous cell lung cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Squamous Cell Non-small Cell Lung Cancer
- Non Small Cell Lung Cancer
- Non-squamous Non-small Cell Lung Cancer
- Squamous Non-small-cell Lung Cancer
- Lung Cancer Non-Small Cell Cancer (NSCLC)
- Metastatic Non-squamous Non Small Cell Lung Cancer
- Advanced Non-squamous Non-small-cell Lung Cancer
- Small Cell Lung Cancer
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.